The U.S. Food and Drug Administration has approved a new cholesterol-lowering medication.
Esperion's Nexletol is a once-daily tablet which is an alternative for millions of patients that cannot take, or don't respond well, to statins.
The company says it's the first oral non-statin drug approved in nearly two decades.
During studies, the drug reduced cholesterol in patients by an average of 18% when used with moderate or high intensity statins.
Nexletol could become available as early as late March.